ClinicalTrials.gg
CompletedNCT03200340Updated Jul 27, 2023

EC-18 for Oral Mucositis in Patients With Concomitant Chemoirradiation

A Phase 2 interventional study of EC-18 and Placebo in Stomatitis, sponsored by Enzychem Lifesciences Corporation. Completed at 20 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-07-27.

Sponsored by Enzychem Lifesciences Corporation · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was May 2021, 5 years 6 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
105
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 80 studies in Stomatitis with a site in United States — 12 open to participants now, 15 under way, none of them phase 3. Stomatitis · United States.

Enrollment
19th of 73
105 · median 60
Started
2018
with 7 others
Phase 2
33 of 80
2 open now
Registered
48th of 80
by date

Among the 80 studies in Stomatitis with a site in United States, this one is the 19th largest by enrollment of the 73 interventional ones that give a count, is one of 8 that started in 2018, is one of 33 in phase 2, and was the 48th registered.

Stomatitis

306 studies on the registry are indexed under Stomatitis; 74 are open to participants now.

Browse Stomatitis studies →

Open to participants now

12 of the 80 studies in Stomatitis with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 45 Stomatitis studies recruiting now, 20 (44%) set no upper age limit and 21 (47%) stop at 75 or younger; 10 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies in Stomatitis with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 2, randomized, double-blind, placebo-controlled, 2-stage trial in subjects with squamous cell cancers of the mouth, oropharynx, hypopharynx and nasopharynx planned to receive standard fractionated IMRT-delivered radiotherapy with concomitant chemotherapy (cisplatin). Informed consent will be obtained from each subject prior to enrollment.

The trial will be performed in 2 stages:

Stage 1 will consist of a blinded parallel group safety study of 4 cohorts in which 24 subjects will be randomized (1:1:1:1) into four equally sized groups to receive one of three doses of EC-18 (500 mg, 1000 mg, 2000 mg; unit dose of 500 mg) or placebo. Stage 2 of the study will evaluate both safety and efficacy.

Stage 2 will consist of eighty (80) subjects who will be randomized in a 1:1 scheme to receive either placebo or 2000 mg of EC-18 as determined by iDSMB in Stage 1.

Read the detailed description

This is a Phase 2, randomized, double-blind, placebo-controlled, 2-stage trial in subjects with squamous cell cancers of the mouth, oropharynx, hypopharynx and nasopharynx planned to receive standard fractionated IMRT-delivered radiotherapy with concomitant chemotherapy (cisplatin). Informed consent will be obtained from each subject prior to enrollment.

The trial will be performed in 2 stages:

Stage 1 will consist of a blinded parallel group safety study of 4 cohorts in which 24 subjects will be randomized (1:1:1:1) into four equally sized groups to receive one of three doses of EC-18 (500 mg, 1000 mg, 2000 mg; unit dose of 500 mg) or placebo delivered in the following daily schedule:

TDD AM PM Placebo 2 placebo 2 placebo 500mg 1 active + 1 placebo 2 placebo 1000mg 1 active + 1 placebo 1 active + 1 placebo 2000mg 2 active 2 active Dosing will commence on the first day of radiation (one hour after the first fraction) and continue until the last day of radiation. Test drug will be administered as an oral 500 mg capsule in divided daily doses as indicated above. At the completion of 4 weeks of dosing, an independent Data Safety Monitoring Board (DSMB) will evaluate safety endpoints in blinded fashion. If no safety issues are identified, the DSMB will approve continuation of dosing until the last day of radiation. If a safety issue is noted, the DSMB may unblind the treatment assignment to ascertain if the adverse event is associated with study drug. DSMB assessment will be repeated after completion of dosing (when each subject has been dosed through the last day of radiation). If no safety issues are identified, the efficacy component of the study (Stage 2) will commence using the highest dose of study drug consistent with a positive safety outcome.

Stage 2 of the study will evaluate both safety and efficacy. Eighty (80) subjects will be randomized in a 1:1 scheme to receive either placebo or 2000 mg of EC-18 as determined by iDSMB in Stage 1. Twice daily dosing will begin on the first day of radiation (1 hour after the first fraction) and continue until the last day of radiation (approximately 7 weeks).

The study will be performed in four phases: screening, the active dosing phase, short-term follow-up and long-term follow-up. The screening phase will be performed within 4 weeks of randomization and will determine subjects' eligibility. The active phase will begin on the first day of study drug dosing (also the first day of radiation therapy) and will continue until the last day of radiation therapy. This period typically is 7 weeks depending on the subject's radiation plan. The short-term follow-up phase will begin on the last day of radiation and continue for approximately 4-6 weeks until clinical and symptomatic signs of oral mucositis have resolved. The long-term follow-up phase extends for 12 months following the last dose of radiation and is included to assure that EC-18 does not the impact of tumor response to treatment.

03

Conditions studied

  • Stomatitis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed
  • Male or female age 18 years or older
  • confirmed diagnosis of squamous cell carcinoma of the mouth, oropharynx, hypopharynx or nasopharynx
  • Planned to receive IMRT with daily fractions of 2.0 Gy to 2.2 Gy to a cumulative dose of at least 60 Gy and a maximum of 72 Gy
  • Radiation fields to include at least two mucositis sites at risk (buccal mucosa, floor of mouth, ventral and lateral tongue, soft palate) in which both sites receive a minimum cumulative dose of 55 Gy
  • Planned to receive concomitant single agent chemotherapy with cisplatin given either weekly or tri-weekly
  • (ECOG) Performance Status ≤ 1
  • Screening Laboratory Values ≥ 9g/dL White blood cell count ≥ 3,500 cells/mm3 ≥ 1,500 cells/mm3 Total ≤ 2 times Serum and ALT ≤ 2.5 times upper limit of normal Serum creatinine concentration ≤ 2mg/mL Pregnancy test: negative for females of
  • Subjects of childbearing potential must consent to utilize a medically accepted means of throughout the active dosing period with study medication and for a minimum of 30 days following the administration of the last dose of study medication.

Exclusion criteria

Exclusion Criteria:

  • Unable to provide or, in the opinion of the Principal Investigator, comply with the protocol.

    • Prior radiation therapy to the head and neck
    • disease
    • Presence of active infectious disease excluding oral candidiasis
    • Presence of oral mucositis or any oral lesion that would confound the assessment of oral mucositis
    • Active systemic disease or condition known to impact the risk or course of oral mucositis including chronic and known seropositivity for
    • Use of any agent within 30 days of the first radiation dose
    • Active alcohol abuse syndrome
    • Subjects with a history of hepatitis of any etiology or hepatic insufficiency
    • Pregnant or nursing at the time of signing informed consent
    • Known sensitivity to any study medication
    • Unwilling or unable to complete study diary
    • Any other condition or prior therapy that, in the opinion of the Investigator, would make the subject unsuitable for the study or unable to comply with the protocol
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
105 participants (actual)

Study arms

  • Placebo comparator
    [Part 1] Placebo

    Matching placebo

    Drug: Placebo

  • Experimental
    [Part 1] EC-18 500 mg

    1 capsule of EC-18

    Drug: EC-18

  • Experimental
    [Part 1] EC-18 1000 mg

    2 capsules of EC-18 500 mg

    Drug: EC-18

  • Experimental
    [Part 1] EC-18 2000 mg

    4 capsules of EC-18 500 mg

    Drug: EC-18

  • Placebo comparator
    [Part 2] Placebo

    Placebo 2000mg

    Drug: Placebo

  • Experimental
    [Part 2] EC-18 2000mg

    RP2D: EC-18 2000mg (Part 1 result)

    Drug: EC-18

Interventions

  • DrugMosedipimodStudies of MosedipimodMosedipimod pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Oral administration of EC-18 twice daily

    Also known as: EC-18 soft capsules

  • DrugPlacebo

    Placebo to match EC-18 capsule administration

    Also known as: Placebo capsule

06

What researchers measure

Primary outcomes

  1. Duration of Severe Oral Mucositis (SOM) during the active treatment and short-term follow-up periods

    Duration of Grade 3 or 4 oral mucositis

    Time frame: 7 Weeks (Active) + 4-6 Weeks (STFU)

Secondary outcomes

  1. Duration of SOM during the active treatment period

    Duration of Grade 3 or 4 oral mucositis

    Time frame: 7 Weeks (Active)

  2. Incidence of severe oral mucositis defined as WHO grade of 3 or 4 during the active treatment period

    Incidence of severe oral mucositis defined as WHO grade of 3 or 4

    Time frame: 7 Weeks (Active)

  3. Incidence of severe oral mucositis defined as WHO grade of 3 or 4 during the active treatment and short-term follow-up periods

    Incidence of severe oral mucositis defined as WHO grade of 3 or 4

    Time frame: 7 Weeks (Active) + 4-6 Weeks (STFU)

  4. Incidence of ulcerative mucositis (defined as WHO grade of 2, 3, or 4) during the active treatment period

    Incidence of WHO grade of 2, 3, or 4 ulcerative mucositis

    Time frame: 7 Weeks (Active)

  5. Incidence of ulcerative mucositis (defined as WHO grade of 2, 3, or 4) during the active treatment and short-term follow-up periods

    Incidence of WHO grade of 2, 3, or 4 ulcerative mucositis

    Time frame: 7 Weeks (Active) + 4-6 Weeks (STFU)

  6. Duration of ulcerative mucositis (WHO criteria)

    Duration of grade 3 or 4 ulcerative mucositis

    Time frame: From the onset to the day when ulcerative mucositis has resolved (up to 22 weeks)

  7. Delay in onset of SOM (WHO criteria)

    Time to onset of grade 3 or 4 severe oral mucositis

    Time frame: Start of the radiation treatment (Day 1) until SOM has resolved (up to 22 weeks)

  8. Reduction in patient-reported mucositis-related mouth pain and analgesic use

    Frequency of disease-related mouth pain and analgesic use

    Time frame: 7 Weeks (Active) + 4-6 Weeks (STFU)

Other outcomes

  1. Duration of severe oral mucositis as defined by RTOG criteria

    Duration of severe oral mucositis based on RTOG criteria

    Time frame: 7 Weeks

  2. Incidence of severe oral mucositis as defined by RTOG criteria

    Incidence of severe oral mucositis as defined by RTOG criteria

    Time frame: 7 Weeks

  3. Duration of severe oral mucositis as defined by NCI-CTCAE v.4 criteria

    Duration of severe oral mucositis based on NCI-CTCAE v.4 criteria

    Time frame: 7 Weeks

  4. Incidence of severe oral mucositis as defined by NCI-CTCAE v.4 criteria

    Incidence of severe oral mucositis based on NCI-CTCAE v.4 criteria

    Time frame: 7 Weeks

  5. Patient reported outcomes as measured by the Oral Mucositis Daily Questionnaire (OMDQ)

    Patient reported outcomes based on 0-4 and 0-10 scales (measuring quality of life)

    Time frame: 7 Weeks (Active) + 4-6 Weeks (STFU)

  6. Patient reported outcomes as measured by Weekly Functional Assessment of Cancer Therapy-for Patients with Head & Neck Cancer (FACT-HN)

    Patient reported outcomes based on 0-4 scale (measuring quality of life)

    Time frame: 7 Weeks (Active) + 4-6 Weeks (STFU)

  7. Breaks in radiation delivery

    Frequency of interruptions in radiation therapy

    Time frame: 7 Weeks

  8. Break duration in radiation delivery

    Duration of interruptions in radiation therapy

    Time frame: 7 Weeks

  9. Healthcare resource use including reliance on gastrostomy feeding, unplanned office visits, emergency room visits, and hospitalizations

    Number of subjects who utilized healthcare resources listed above

    Time frame: 7 Weeks (Active) + 4-6 Weeks (STFU)

07

Study locations

20 sites
  • Veterans Affairs Long Beach Health Care System
    Long Beach, California 90822, United States
  • UCLA Jonsson Comprehensive Cancer Center
    Los Angeles, California 90095, United States
  • Mount Sinai Comprehensive Cancer Center
    Miami Beach, Florida 33140, United States
  • Miami Cancer Institute
    Miami, Florida 33176, United States
  • Winship Cancer Institute of Emory University
    Atlanta, Georgia 30322, United States
  • NorthShore University HealthSystem
    Evanston, Illinois 60201, United States
  • Southern Illinois University School of Medicine
    Springfield, Illinois 62702, United States
  • Cancer Center of Kansas
    Wichita, Kansas 67214, United States
  • University of Kentucky, Chandler Medical Center, CCTS
    Lexington, Kentucky 40536, United States
  • Greater Baltimore Medical Center
    Baltimore, Maryland 21204, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110-1010, United States
  • Mount Sinai - Union Square
    New York, New York 10003, United States
  • University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma 73104, United States
  • Oregon Health and Science University
    Portland, Oregon 97239, United States
  • VA Portland HealthCare System
    Portland, Oregon 97239, United States
  • St. Luke's Cancer Center - Anderson Campus
    Easton, Pennsylvania 18045, United States
  • Hope Cancer Center of East Texas
    Tyler, Texas 75701, United States
  • Baylor Scott & White Medical Center - Hillcrest
    Waco, Texas 76712, United States
  • MultiCare Institute for Research and Innovation
    Spokane, Washington 98405, United States
  • MultiCare Institute for Research and Innovation
    Tacoma, Washington 98405, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2018 to primary completion in May 2021, 34 months.

Of 39 phase 2 interventional studies under Stomatitis, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 48. This study's 34 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2017
First posted
Jun 27, 2017
StartActual
Jul 3, 2018
Primary completionActual
May 14, 2021
CompletionActual
May 14, 2021
Last update
Jul 27, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03200340
Lead sponsor
Enzychem Lifesciences Corporation
Responsible party
Sponsor
First posted
Jun 27, 2017
Start date
Jul 3, 2018
Primary completion
May 14, 2021
Completion
May 14, 2021
Last update
Jul 27, 2023

Study contacts

Dong Moon Shin, MD
principal investigator · Emory University Winship Cancer Institute
Mahesh Kudrimoti, MD
principal investigator · University of Kentucky, Chandler Medical Center, CCTS

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mosedipimod

Start the discussion